BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, July 13, 2025
See today's BioWorld Asia
Home
» Innovent raises HKD$4.3B to advance R&D pipeline, global expansion
To read the full story,
subscribe
or
sign in
.
Innovent raises HKD$4.3B to advance R&D pipeline, global expansion
July 1, 2025
By
Tamra Sami
No Comments
Innovent Biologics Inc. announced a HKD$4.3 billion (US$547 million) placement on the Hong Kong Stock Exchange to advance its R&D projects and to fund its global expansion.
BioWorld Asia
Financings
Cancer
Diabetes
Endocrine/metabolic
Obesity
Oncology
Mezzanine
Asia-Pacific
China
